

N.K.CORE DIAGNOSTICS

Patient Name : NEW PATIENT CHECK

Referral : Dr. tempo a

Report Date : Feb 18, 2026, 11:49 a.m.

Sample Date : Feb 18, 2026, 11:48 a.m.

Age : 0 days (Male)

Reg. ID : I - 1217

Sample ID : 260218003

Your Test Results

Test 12

Test Description	Value(s)	Reference Range
Test 12	12	12 - 122

END OF REPORT

A BSE Listed Company
022-71975756

report@aspiradiagnostics.com
www.aspiradiagnostics.com

* Mark Test is not under NABL Scope

REPORT

N.K.CORE DIAGNOSTICS

Patient Name : NEW PATIENT CHECK

Age : 0 days (Male)

Referral : Dr. tempo a

Reg. ID : I - 1217

Report Date : Feb 18, 2026, 01:11 p.m.

Sample Date : Feb 18, 2026, 11:48 a.m.

Sample ID : 260218003

Your Test Results

Test 11

Test Description	Value(s)	Reference Range
Test 11	12	10 - 100

END OF REPORT

A BSE Listed Company
022-71975756

report@aspiradiagnostics.com
www.aspiradiagnostics.com

* Mark Test is not under NABL Scope

REPORT

N.K.CORE DIAGNOSTICS

Patient Name : NEW PATIENT CHECK

Age : 0 days (Male)

Referral : Dr. temple a

Reg. ID : I - 1217

Report Date : Feb 18, 2026, 01:12 p.m.

Sample Date : Feb 18, 2026, 11:48 a.m.

Sample ID : 260218003

Your Test Results

<u>test66</u>		
Test Description	Value(s)	Reference Range
d	12	2 - 4
c	21	4 - 9
b	12	1 - 11
a	12	7 - 14
Descriptive (No Ranges)	• CREATININE was ABNORMAL in this sample, suggesting that it may have been diluted or otherwise constructed • PH was ABNORMAL in this sample. Does the patient have a medical condition that could account for this? If not, tampering must be considered. • SPECIFIC-GRAVITY was ABNORMAL in this sample. Does the patient have a medical condition that could account for this? If not, tampering must be considered.	

END OF REPORT

A BSE Listed Company

022-71975756

report@aspiradiagnostics.com

www.aspiradiagnostics.com

* Mark Test is not under NABL Scope

REPORT